PAST MEDICAL HISTORY
The patient was a healthy term infant born in the Washington, DC, area to a healthy 28-year-old G1P1 (1 pregnancy, 1 term birth) woman via spontaneous vaginal delivery. Her birth weight was 2.9 kg, and she received the hepatitis B vaccine after birth. When the patient was 1 month old, she traveled with her mother to Honduras, where she spent 40 days in a suburban area of Tegucigalpa before returning to Washington, DC. During the trip, she was breastfed exclusively, and her health was unremarkable; she experienced no illnesses or exposure to the jungle or animals. However, 20 days before returning to the United States, her mother had developed high fevers, joint pain, malaise, headaches, and vomiting, and she was diagnosed with chikungunya virus solely on the basis of her clinical findings and symptoms, which began to resolve after 7 days. The patient's symptoms began within 6 days of returning home with a rash and fever.
MEDICATIONS
No medications were given to the patient before her presentation to the emergency department.
FAMILY HISTORY
The mother and father were both healthy and were originally from Honduras. The mother stated that she had not experienced symptoms of chikungunya virus before this episode.
PHYSICAL EXAMINATION
The patient's weight, length, and head circumference were all appropriate for her age. Her vital signs 10 hours after triage and after being intubated and placed on mechanical ventilation included a blood pressure of 61/32 mm Hg after 4 boluses (20 ml/kg each) of normal saline, a pulse of 172 beats per minute, a temperature of 39.2°C, and a respiratory rate of 12 breaths per minute. Significant findings on her physical examination included generalized swelling, tachycardia, and poor air entry bilaterally. A diffuse maculopapular rash was noted throughout her trunk, face, and extremities (Figures 1 and 2 ).
INITIAL LABORATORY AND RADIOGRAPHIC FINDINGS
The infant's white blood cell count was 7.1 × 10 3 µL (reference range, 6-13 × 10 3 µL) with no bands and 77% segmented neutrophils. Her platelet count was 324 × 10 3 µL (reference range, 100-500 × 10 3 µL). Her liver enzyme levels were normal. Results of a malaria slide review were negative. Blood and urine cultures were performed. The infant was initially too unstable for us to perform a lumbar puncture. A chest radiograph revealed a small area of atelectasis on the left side but no focal pneumonia.
Broad-spectrum antibiotic coverage was started with vancomycin and ceftriaxone. After initial fluid resuscitation and the initiation of vasoactive infusions, the vasoactives were gradually weaned over 4 days, and the patient was extubated on the sixth day of admission. The patient's rash gradually resolved over 10 days.
DIAGNOSTIC PROCEDURE AND RESULTS
A cerebrospinal fluid examination could not be performed initially because of the infant's instability. Results of a lumbar puncture performed on the third day of admission after 48 hours of antibiotics were unremarkable, with 0 white blood cells per µL, 10 red blood cells per µL, a glucose level of 73 mg/dL, and a protein level of 35 mg/dL. Gram staining revealed rare erythrocytes and no organisms. Test results of a nasopharyngeal swab to detect common viruses such as respiratory syncytial virus, human metapneumovirus, influenza, parainfluenza, rhinovirus, enterovirus, and adenovirus were also negative. Blood, urine, and cerebrospinal fluid cultures resulted in no growth. Dengue titers were negative. Results of the brain magnetic resonance imaging with and without contrast were normal.
DIAGNOSIS
Chikungunya infection was high in the differential on the basis of the mother's recent infection and exposures. Results of a test of the infant's mixed-serum immunoglobulin G (IgG) and IgM titers for chikungunya virus were positive, but it was unclear if this positivity was a result of the infant's infection or a previous infection of the mother. Results of a commercial qualitative real-time polymerase chain reaction (PCR) assay for chikungunya virus RNA from the serum also were positive, which confirmed the diagnosis. Her diagnosis was septic shock secondary to chikungunya virus infection.
TREATMENT AND FOLLOW-UP
Ceftriaxone and vancomycin were continued for a total of 10 days to treat the patient for culture-negative sepsis. Chikungunya virus results arrived on the eighth day of hospitalization. By the ninth day of admission, the patient was back to her normal health; she was breastfeeding regularly again and engaging in an appropriate level of activity for her age. The patient was discharged after completing 10 days of antibiotics. Because chikungunya virus infection is a nationally notifiable disease, this case was reported to the local health department.
BRIEF DISCUSSION AND MAJOR TEACHING POINTS
This case describes an infant who presented to the emergency department in septic shock secondary to chikungunya virus infection.
Chikungunya fever was first reported in 1952 from the Makonde plateaus of Tanzania and Mozambique [1] . Chikungunya is a small spherical single-stranded RNA arbovirus (genus Alphavirus, family Togaviridae) [1] . It probably originated in Africa, where it maintained its existing cycle by involving wild primates and forest-dwelling mosquitoes [2, 3] . Before 2013, all travelers infected with chikungunya virus were returning from Asia, Africa, or the Indian Ocean [2] . This virus first moved into the Western Hemisphere in 2013 and has continued to spread. In 2014, chikungunya virus in travelers to the Americas and Caribbean was reported, and local transmission in Florida, Puerto Rico, and the US Virgin Islands was identified [2] . As of 2017, 37 states reported that all cases with illness onset in 2016 were associated with travel [2] .
Transmission of the virus to humans is mainly through the Aedes genus of mosquitoes [1] [2] [3] . Common reservoirs for chikungunya virus are monkeys and other vertebrates [3] . After inoculation by an infected mosquito, the chikungunya virus replicates in the skin and then disseminates to the liver, muscle, joint lymphoid tissue (lymph nodes and spleen), and brain, presumably through the blood [3] .
Typical symptoms of chikungunya virus include high fever (up to 105°F), arthralgia, arthritis, headache, photophobia, and a petechial or maculopapular rash [3] . Polyarthralgia of the distal joints can be severe and incapacitating. The acute phase of the virus lasts from a few days to a couple of weeks [1] [2] [3] . The arthralgia and myalgia have been known to persist in adults from months to years [3] . Limited communication skills in infants results in difficulty determining if the characteristic joint pain that is often seen is present, which makes the clinical diagnosis more difficult to make. The cutaneous manifestations can also differ between infants and adults; infants can present with pigmentation, vesicles, and bullae [4] . In cases of congenital chikungunya virus infection, neonates can develop pigmentation in their face, chest, and extremities [5] . Pigmentation would be an unlikely finding in infants and children with presumed mosquito transmission.
Septic shock caused by chikungunya virus, as occurred in our patient, is a rare occurrence. Severe life-threatening complications have been observed during the acute phase [6] . Although bacterial coinfection with chikungunya virus has seemed unlikely to date, the literature has documented severe bacterial coinfections with viral infections such as influenza and dengue [6] . These data supported our decision to administer a course of antibiotics for culture-negative sepsis in our patient.
Laboratory abnormalities during the acute phase of the illness can include elevation of liver and muscle enzyme levels, thrombocytopenia, and/or leukopenia [1] [2] [3] 7] . Diagnostic laboratory studies rely on detection of the virus with antichikungunya IgM and IgG, viral culture, or real-time reverse-transcription PCR (RT-PCR) performed on blood samples. Antichikungunya antibodies can typically be detected in patients shortly after symptom onset, usually 5 days for IgM and only a few days later for IgG [2, 7] . A viral culture can isolate the virus in the first 3 days of illness, whereas commercial kits such as the chikungunya virus RT-PCR kit also have high sensitivity and specificity for viral RNA [2, 7] . Because of the cross-reactivity between dengue, Zika, and other flavivirus IgM immunoassays, and the possibility of coinfection with dengue, Zika, and chikungunya because of vector distribution, it is important to evaluate cases by using viral PCR to identify the causative agent [7] .
There is no specific treatment or vaccine against chikungunya virus available. Because the illness resolves with time, all that is typically provided is supportive care and rest. The overall mortality rate attributable to chikungunya virus is low, but infants, the elderly, and those with concurrent diseases can have more severe disease [2, 3] . It is advisable that those infected with the virus stay indoors during the first few days of illness so that they do not contribute to the cycle, because mosquitoes can become infected while feeding on an individual infected with chikungunya virus.
Providers should be more cognizant of chikungunya virus as a possible etiology in younger children and infants who present with high fever and rash, even in the absence of arthralgia.
